Bristol’s eXmoor Pharma appoints chief technology officer


eXmoor Pharma has appointed Dr.Lucy Foley as Chief Technology Officer. Lucy joins eXmoor after eight years at the Centre for Process Innovation (CPI) with her most recent position as Director of Biologics and COVID response.

Lucy brings with her more than 10 years of industry experience focused on technology, process development and delivering large, complex projects. Her role will see her oversee the vector, analytics, cell therapy, and project verticals.

Lucy recently led the establishment of the UK’s RNA Centre of excellence in response to the COVID-19 pandemic as a member of the UK Vaccines Taskforce. This established both PD and GMP facilities in the UK to provide resilience against future variants and pandemics by onshoring manufacturing and expertise.

In 2013, as the Lead Biopharmaceutical Engineer at CPI, Lucy collaborated with eXmoor on the concept design of the organisation’s Darlington-based National Biologics Manufacturing Centre.

Previously, she was an academic at Newcastle University in both the Business School and Chemical Engineering Departments where she worked with Professors Lyddiatt and Whitaker to understand the route to widespread adoption and process industrialisation of advanced therapies.

Lucy is already a familiar face to the eXmoor team as she serves as a founding leadership team member on the amc (ATMP Manufacturing Community) board alongside eXmoor CEO, Dr. Angela Osborne.

Angela said: “Lucy’s unprecedented industry experience will be integral to the next phase of our growth.”

Lucy holds a master’s degree in biochemical engineering with bioprocess management from University College London, and an engineering doctorate in biochemical engineering and bioprocess leadership from University College London.

With a 40-strong staff team eXmoor Pharma has worked with more than 125 organisations across the globe.

The company was founded in 2004 and has completed more than 300 projects across 12 countries. The team works with clients to help them with commercialising a research process, developing fully licensed facilities, and providing QP services.